ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

April - June 2005, Volume 1, Issue 2
Case Report


Ursu HI, Hortopan D, Podia-Igna C, Vizireanu A, Harsan T, Dumitriu L, Alexandrescu D

Late onset Graves thyrotoxicosis in a patient with 18 years history of euthyroid Graves ophtalmopathy

Acta Endo (Buc) 2005, 1 (2): 227-232
doi: 10.4183/aeb.2005.227

A 38 years old, heavy smoker, was admitted in our thyroid unit in August 1993 with left eye proptosis (21 mm), right eye prosthesis and euthyroidism. Orbital CT scan revealed inferior rectus muscle hypertrophy in the left orbit and possible residual (postoperative) lateral rectus muscle hypertrophy in the right orbit. Left eye proptosis was treated with both glucocorticoids and orbital radiotherapy.\r\nSeven years before (1986) the patient developed right eye proptosis, without clinical features of hyperthyroidism. Being suspected of a sphenoid ring meningioma and since orbital CT scan was not available at that time, a right orbit exploration was performed in November 1987; soon after orbital exploration, clinical features suggesting right orbital cellulitis occurred, followed by right eye evisceration and right eye prosthesis. After 18 years of Graves ophthalmopathy with euthyroidism, in February 2004 an autoimmune hyperthyroidism was diagnosed (suppressed TSH, high TT3, positive TRAb), being successfully treated with radioiodine. One year after the ablative therapy the patient is still euthyroid. A patient with euthyroid Graves ophthalmopathy should be monitored indefinitely, since a thyroid dysfunction may occur even after more than a decade.

Keywords: Graves ophthalmopathy, euthyroidism, orbital CT scan, radioiodine therapy

Correspondence: Horea Ursu, Institute of Endocrinology, 34 - 36 Bd Aviatorilor, Bucharest, Romania, e-mail: hursu@opensys.ro

References:

1. Bahn RS, Heufelder AE. Pathogenesis of Graves ophthalmopathy. N Engl J Med 1993; 329(20): 1468 - 1475.
2. Gerding NM, Terwee CB, Dekker FW, Koornneef L , Prummel MF, Wiersinga WM. Quality of life in patients with Graves ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument.Thyroid 1997; 7(6): 885 - 889. [CrossRef]
3. Bahn RS. Pathophysiology of Graves ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 2003; 88(5): 1939 - 1946. [CrossRef]
4. Wiersinga WM. Preventing Graves ophthalmopathy. N Engl J Med 1998; 338(2): 121 - 122. [CrossRef]
5. Burch HB, Wartofsky L. Graves ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14(6): 747 - 793.
6. Dallow RL. Evaluation of unilateral exophthalmos with ultrasonography: analysis of 258 consecutive cases. Laryngoscope 1975; 85(11): 1905 - 1919. [CrossRef]
7. Bartalena L, Marcocci C, Tanda ML et al. Cigarette smoking and treatment outcome in Graves ophthalmopathy. Ann Intern Med 1998; 129(8): 633 - 635.
8. Bartalena L, Marcocci C, Pinchera A. Graves ophthalmopathy: a preventable disease? Eur J Endocrinol 2002; 146(4): 457 - 461. [CrossRef]
9. Barnes PJ, Karin M. Nuclear Factor - kB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15): 1066 - 1071.
10. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orb [CrossRef]
11. Weissel M, Hauff W. Fatal liver failure after high dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10(6): 521.
12. Martino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves ophthalmopathy. Thyroid 2004; 14(5): 403 - 406. [CrossRef]
13. Gorman CA. Temporal relationship between onset of Graves ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 1983; 58(8): 515 - 519.
14. Ursu H, Hortopan D, Alexandrescu D, Coculescu M. An unusual side effect of glucocorticoid therapy in Graves ophthalmopathy. Romanian Journal of Endocrinology and Metabolism 2004; 3(4): 75 - 78.
15. Brokken LJS, Wiersinga WM, Prummel MF. Thyrotropin receptor antibodies are associated with continued thyrotropin suppression in treated euthyroid Graves disease patients. J Clin Endocrinol Metab 2003; 88(9): 4135 - 4138. [CrossRef]